Sutro Biopharma (NASDAQ:STRO – Get Free Report) and Genmab A/S (NASDAQ:GMAB – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.
Profitability
This table compares Sutro Biopharma and Genmab A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sutro Biopharma | -344.22% | N/A | -76.33% |
| Genmab A/S | 16.97% | 13.67% | 6.42% |
Volatility and Risk
Sutro Biopharma has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
Valuation & Earnings
This table compares Sutro Biopharma and Genmab A/S”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sutro Biopharma | $102.48 million | 1.51 | -$191.09 million | ($11.97) | -0.78 |
| Genmab A/S | $3.72 billion | 8.65 | $963.00 million | $1.17 | 44.08 |
Genmab A/S has higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations and price targets for Sutro Biopharma and Genmab A/S, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sutro Biopharma | 1 | 0 | 10 | 2 | 3.00 |
| Genmab A/S | 0 | 1 | 10 | 1 | 3.00 |
Sutro Biopharma presently has a consensus target price of $49.60, indicating a potential upside of 432.19%. Genmab A/S has a consensus target price of $53.50, indicating a potential upside of 3.74%. Given Sutro Biopharma’s higher probable upside, equities analysts clearly believe Sutro Biopharma is more favorable than Genmab A/S.
Summary
Genmab A/S beats Sutro Biopharma on 8 of the 13 factors compared between the two stocks.
About Sutro Biopharma
Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.
About Genmab A/S
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
